Research graph
References from New leads to enhance tagraxofusp efficacy in pDC-AML. Local targets link to admitted publications; unresolved targets remain external evidence.
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia
10.1182/blood.2020007897 · 2021 · External reference
Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape
10.3324/haematol.2020.253740 · 2021 · External reference
Neoplasms derived from plasmacytoid dendritic cells
10.1038/modpathol.2015.145 · 2016 · External reference
Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm
10.1182/bloodadvances.2019000173 · 2020 · External reference
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia
10.1038/s41375-019-0447-3 · 2019 · External reference
Plasmacytoid dendritic cell infiltration in acute myeloid leukemia
10.2147/cmar.s260825 · 2020 · External reference
Signalling by the βc family of cytokines
10.1016/j.cytogfr.2013.03.002 · 2013 · External reference
Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm
10.3324/haematol.2017.169326 · 2017 · External reference
Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition
10.1038/leu.2014.64 · 2014 · External reference
Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer
10.1038/s41375-018-0117-x · 2018 · External reference
BCL-2 expression is mainly regulated by JAK/STAT3 pathway in human CD34+ hematopoietic cells
10.1038/sj.cdd.4402007 · 2007 · External reference
The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers
2008 · External reference
The role of PLCγ2 in immunological disorders, cancer, and neurodegeneration
10.1016/j.jbc.2021.100905 · 2021 · External reference
Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies
10.1038/s41467-024-45916-6 · 2024 · External reference
Evaluation of tagraxofusp (SL-401) alone and in combination with ruxolitinib for the treatment of myeloproliferative neoplasms
10.1182/blood-2019-129397 · 2019 · External reference
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
10.1200/jco.2005.14.415 · 2005 · External reference
